Plasmapheresis in collagen vascular diseases

Therapeutic Apheresis

Volumn 3, Issue 2, 1999, Pages 172-177

  Lewis, Edmund J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APLASTIC ANEMIA; COLLAGEN DISEASE; CONFERENCE PAPER; HUMAN; LUNG HEMORRHAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROANGIOPATHY; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE;

ARTHRITIS, RHEUMATOID; COLLAGEN DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMAPHERESIS; VASCULAR DISEASES;

EID: 0032977324     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.1999.00148.x     Document Type: Conference Paper

References (58)

1. Roberts JL, Robinson MF, Lewis EJ. Low molecular weight plasma cryoprecipitable anti-native DNA: Polynucleotide complexes in lupus glomerulonephritis. Clin Immunol Immunopathol 1981;19:75-90.
2. Berden JHM. Lupus nephritis. Nephrology Forum. Kidney Int 1997;52:538-58.
3. Jones JV, Bucknall RC, Cumming RH, Bacon PA. Plasmapheresis in the management of systemic lupus erythematosus? Lancet 1976;1:709-711.
4. Jones JV, Cumming RC, Bacon PA. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 1979;48:555-76.
5. Frank MM, Hamburger MI, Lowley TJ, Kimberly RP, Plotz PH. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 1979;300: 518-23.
6. Lockwood CM, Worlledge S, Nicholas A. Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 1979;300:524-30.
7. Vangelista A, Frasca GM, Ananni-Costa A, Bonomini V. Effect of plasmapheresis on E-rosette receptors in SLE patients. J Clin Apheresis 1986;3:100-2.
8. Low A, Hotze A, Krapf F, Schranz W, Manger BJ, Mahlsedt J, Wolf F, Kalden JR. The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis. Rheum Int 1985;5:69-72.
9. Bonomini V, Vangelista A, Frasca GM, Nanni-Costa A, Borgino LC. The effect of plasmapheresis on cellular immunity abnormalities in patients with systemic lupus erythematosus. Clin Nephrol 1984;22:121-6.
10. Lewis EJ. Plasmapheresis for the treatment of severe lupus nephritis: Uncontrolled observations. Am J Kidney Dis 1982;2(Suppl. 1):86-91.
11. Strauss MB. Milbank Mem Fund Qtr 1969;47(Part 2):80.
12. Clough JD, Lewis EJ, Lachin JM. Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. Progress Clin Biol Res 1990;337:301-7.
13. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373-9.
14. Schroeder JO, Euler HH, Loffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 1987;107:344-6.
15. Euler HH, Schroeder JO, Zeuner RA, Reske E. A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: Design of the LPSG trial. Int J Artif Organs 1991;14:639-46.
16. Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 1991;18:270-6.
17. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gotschmidt HJ. Treatment free remission in severe lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994;37:1784-94.
18. Clark WF, Dau PC, Euler HH. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus. J Clin Apheresis 1991;6:40-7.
19. Hanly JG, Hong C, Zayed E, Jones JV, Jones E. Immunomodulating effects of synchronized plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 1995;4:457-63.
20. Eagen JW, Memoli VA, Roberts JL, Matthew GR, Schwartz MM, Lewis EJ. Pulmonary hemorrhage in systemic lupus erythematosus. Medicine 1978;57:545-60.
21. Eagen JW, Roberts JL, Schwartz MM, Lewis EJ. The composition of pulmonary immune deposits in systemic lupus erythematosus. Clin Immunol and Immunopathol 1979;12: 204-19.
22. Erickson RW, Franklin WA, Emlen W. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 1994;24:114-23.
23. Isbister JP, Ralston M, Hayes JM, Wright R. Fulminant lupus pneumonitis with acute renal failure and RBC aplasia. Successful management with plasmapheresis and immunosuppression. Arch Intern Med 1981;141:1081-3.
24. Koh WH, Thumboo J, Boey ML. Pulmonary hemorrhage in Oriental patients with systemic lupus erythematosus. Lupus 1997;6:713-6.
25. Samora MR, Warner ML, Tueder R, Schwartz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival and outcome. Medicine 1997;76:192-202.
26. Love PE, Santoro SA. Anti-phospholipid antibodies: Anticardiolipin and the lupus anticoagulant in SLE and in SLE disorders. Ann Intern Med 1990;112:682-98.
27. Escalant A, Brey RL, Mitchell BD, Dreiner U. Accuracy of anti-cardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995;98:559-65.
28. Khamashta MA, Cuadrado MJ, Mujic F. The management of thrombosis in the anti-phospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
29. Kobayashi S, Tamura N, Tsuda H. Immunoadsorbent plasmapheresis for a patient with anti-phospholipid syndrome during pregnancy. Ann Rheum Dis 1992;51:399-401.
30. Lockshin MD. Answers to the anti-phospholipid antibody syndrome. N Engl J Med 1995;332:1025-7.
31. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, Lim K, Munoz-Rodriguez FJ, Levy RA, Boue F, Rossert J, Ingelmo M. The catastrophic anti-phospholipid syndrome. Medicine 1998;77:195-207.
32. Asherson RA, Piette JC. The catastrophic anti-phospholipid syndrome 1996: Acute multiorgan failure associated with anti-phospholipid antibodies: A review of 31 patients. Lupus 1996; 5:414-7.
33. Jain R, Chartash E, Susin M, Furie R. Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum 1994;24:173-82.
34. Neshr G, Hanna VE, Moore TL, Hersh , Osborn TG. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994;24:165-72.
35. Nampoory MR, Johny KV, Gupta RK, Constandi JN, Nair MP, al-Muzeiri I. Treatable intracranial hypertension in patients with lupus nephritis. Lupus 1997;6:597-602.
36. Levine S, Shearn M. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Arch Intern Med 1964;113: 826-36.
37. Moake JL. Moschowitz, multimers, and metalloprotease. N Engl J Med 1998;339:1629-31.
38. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7.
39. Gelfand J, Truong L, Stern L, Pirani CL, Appel GB. Thrombotic thrombocytopenic purpura syndrome in systemic lupus erythematosus: Treatment with plasma infusion. Am J Kidney Dis 1985;6:154-60.
40. Aster RM. Plasma therapy for thrombotic thrombocytopenic purpura. N Engl J Med 1985;312:985-6.
41. Stricker RB, Davis JA, Gershow J, Yamamoto KS, Kiprov DD. Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era. J Rheumatol 1992;19: 1469-73.
42. Newsom-Davis J, Wilson SG, Vincent A. Long term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979; 1:464-8.
43. Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982;11:570-5.
44. Deodhar A, Norden J, So Y, Bennett R. The association of systemic lupus erythematosus and the Lambert-Eaton myasthenic syndrome. J Rheumatol 1996;23:1292-4.
45. Fitchen JJ, Cline MJ, Saxon A. Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: Recovery after exchange plasmapheresis. Am J Med 1979;66:537-42.
46. Brooks VJ Jr., Broxmeyer HE, Bryan CF, Leech SH. Serum inhibitor in systemic lupus erythematosus associated with aplastic anemia. Arch Intern Med 1984;144:1474-7.
47. Finkelstein Y, Adler Y, Harel L, Nussinovitch M, Youinou P. Anti-Ro (SSA) an anti-La (SSB) antibodies and complete congenital heart block. Ann Med Intern 1997;148:205-8.
48. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757-63.
49. Glockner WM, Sieberth HG, Wichmann HE. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis. Clin Nephrol 1988;29:1-8.
50. Rifle G, Dechelett E. Treatment of rapidly progressive glomerulonephritis by plasma exchange and methylprednisolone pulses: A prospective randomized trial of cyclophosphamideinterim analysis: The French Cooperative Group. Prog Clin Biol Res 1990;337:263-7.
51. Frasca GM, Zoumparidis NG, Borgino LC, Neri L, Vangelista A, Bonomini V. Plasma exchange treatment in rapidly progressive glomerulonephritis associated with anti-neutrophil cytoplasmic autoantibodies. Int J Artif Organs 1992;15:181-4.
52. Jennette JC, Falk RJ. Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies. Lab Invest 1994;70:135-7.
53. Karsh J, Klippel JH, Potz PH. Lymphapheresis in rheumatoid arthritis: A randomized trial. Arthritis Rheum 1981;24:867-73.
54. Dwosh IL, Giles AR, Ford PM. Plasmapheresis therapy in rheumatoid arthritis: A controlled, double-blind cross over trial. N Engl J Med 1983;308:1124-9.
55. Scofield RH, Tardibono G, Ogden SB, Harley JB, Reichlin M, Kurin BT. Rheumatoid hyperviscosity: Analysis of a patient with intermediate complexes that block other autoantibodies and a review of the literature. Semin Arthritis Rheum 1998;27:382-91.
56. Crapper RM, Dowling JP, Mackay IR, Whitworth JA. Acute scleroderma in stable mixed connective tissue disease: Treatment by plasmapheresis. Aust NZ J Med 1987;17:327-9.
57. Capodicasa G, DeSanto NG, Galione A, Vinti V, Giannetto D, Annaloro R, Vaccaro F, Bellavia C, Picione F, Riccobene G. Clinical effectiveness of apheresis in the treatment of progressive systemic sclerosis. Int J Artif Organs 1983;6(Suppl. 1):81-6.
58. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380-4.